Literature DB >> 33923400

The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.

Anna Li Santi1, Filomena Napolitano2, Nunzia Montuori2, Pia Ragno1.   

Abstract

Proteolysis is a key event in several biological processes; proteolysis must be tightly controlled because its improper activation leads to dramatic consequences. Deregulation of proteolytic activity characterizes many pathological conditions, including cancer. The plasminogen activation (PA) system plays a key role in cancer; it includes the serine-protease urokinase-type plasminogen activator (uPA). uPA binds to a specific cellular receptor (uPAR), which concentrates proteolytic activity at the cell surface, thus supporting cell migration. However, a large body of evidence clearly showed uPAR involvement in the biology of cancer cell independently of the proteolytic activity of its ligand. In this review we will first describe this multifunctional molecule and then we will discuss how uPAR can sustain most of cancer hallmarks, which represent the biological capabilities acquired during the multistep cancer development. Finally, we will illustrate the main data available in the literature on uPAR as a cancer biomarker and a molecular target in anti-cancer therapy.

Entities:  

Keywords:  cancer hallmarks; uPAR; urokinase receptor

Year:  2021        PMID: 33923400     DOI: 10.3390/ijms22084111

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  17 in total

1.  N,N'-Diphenyldithiomalonodiamide: Structural Features, Acidic Properties, and In Silico Estimation of Biological Activity.

Authors:  A E Sinotsko; A V Bespalov; N V Pashchevskaya; V V Dotsenko; N A Aksenov; I V Aksenova
Journal:  Russ J Gen Chem       Date:  2021-12-17       Impact factor: 0.868

2.  Clinical Efficacy of Xueshuantong plus Urokinase in the Treatment of Sudden Deafness.

Authors:  Yanling Wang; Jian Wang; Xiulan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

3.  Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.

Authors:  Nico Dreymann; Julia Wuensche; Wiebke Sabrowski; Anja Moeller; Denise Czepluch; Dana Vu Van; Susanne Fuessel; Marcus M Menger
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

4.  TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.

Authors:  Tao Zhang; Bofang Wang; Fei Su; Baohong Gu; Lin Xiang; Lei Gao; Peng Zheng; Xue-Mei Li; Hao Chen
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

Review 5.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

6.  Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells.

Authors:  June Yong Park; Yuseon Shin; Woong Roeck Won; Chaemin Lim; Jae Chang Kim; Kioh Kang; Patihul Husni; Eun Seong Lee; Yu Seok Youn; Kyung Taek Oh
Journal:  Int J Nanomedicine       Date:  2021-08-12

Review 7.  Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.

Authors:  Maria Teresa Masucci; Michele Minopoli; Gioconda Di Carluccio; Maria Letizia Motti; Maria Vincenza Carriero
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

8.  Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis.

Authors:  Anna A Shmakova; Polina S Klimovich; Karina D Rysenkova; Vladimir S Popov; Anna S Gorbunova; Anna A Karpukhina; Maxim N Karagyaur; Kseniya A Rubina; Vsevolod A Tkachuk; Ekaterina V Semina
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

9.  PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma.

Authors:  Mulin Liu; Siyi Chen; Aihui Zhang; Qin Zheng; Juan Fu
Journal:  J Inflamm Res       Date:  2021-09-15

Review 10.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.